| Protocol No. | RTOG-1115 | Principal Investigator | Roach III, Mack |
| Phase | III (Cancer Control) |
| Age Group | Adult | Scope | National |
|
| Title | Phase III Trial of Dose Escalated Radiation Therapy and Standard Androgen Deprivation Therapy (ADT) with a GNRH Agonist vs Dose Escalated Radiation Therapy and Enhanced ADT with a GNRH Agonist and TAK-700 for Men with High Risk Prostate Cancer |
| Objective | To evaluate the difference in overall survival in men with clinically localized prostate cancer with unfavorable prognostic features between a) standard treatment (ADT + radiotherapy) and b) standard treatment with the addition of 24 months of TAK-700. |
|
|
| Key Eligibility | * Histologically confirmed diagnosis of adenocarcinoma of the prostate
* Clinically negative lymph nodes as established by imaging |
| Applicable Disease Sites | Prostate |
|
|
| Drugs Involved | Orteronel |
| Status | Open |
| Participating Institutions | Mt. Zion : Paula Dutton |
|
| Eligibility Document | RTOG-1115_CTGovEligibility_NCT01546987.doc |
|
| Contact | Paula Dutton |
Phone:
Pager:
Email:walshp@medicine.ucsf.edu |